Analysts expect Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) to report earnings per share of ($0.19) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Cyclacel Pharmaceuticals’ earnings. Cyclacel Pharmaceuticals reported earnings of ($0.12) per share in the same quarter last year, which would indicate a negative year over year growth rate of 58.3%. The business is expected to announce its next earnings results after the market closes on Tuesday, May 14th.
According to Zacks, analysts expect that Cyclacel Pharmaceuticals will report full year earnings of ($0.77) per share for the current financial year, with EPS estimates ranging from ($0.86) to ($0.68). For the next financial year, analysts forecast that the firm will report earnings of ($0.80) per share. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Cyclacel Pharmaceuticals.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings data on Wednesday, March 27th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.17). The firm had revenue of $0.15 million during the quarter.
A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Raymond James Financial Services Advisors Inc. grew its stake in shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 49.9% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 75,125 shares of the biotechnology company’s stock after acquiring an additional 25,000 shares during the period. Raymond James Financial Services Advisors Inc. owned about 0.44% of Cyclacel Pharmaceuticals worth $70,000 at the end of the most recent reporting period. Institutional investors own 2.95% of the company’s stock.
Shares of CYCC stock opened at $0.69 on Thursday. Cyclacel Pharmaceuticals has a 52-week low of $0.51 and a 52-week high of $1.87. The stock has a market capitalization of $11.95 million, a price-to-earnings ratio of -1.12 and a beta of 3.36.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.
Featured Story: Bar Chart
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.